Go to ...


Value Investing Research Since 2006

RSS Feed

Wednesday, September 20, 2017

Endo International PLC Valuation – July 2017 $ENDP

Benjamin Graham taught that Intelligent Investors must do a thorough fundamental analysis of investment opportunities to determine their intrinsic value and inherent risk.  This is best done by utilizing a systematic approach to analysis that will provide investors with a sense of how a specific company compares to another company or by reviewing the 10 Stocks for Using A Benjamin Graham Value Investing Strategy – March 2017.  By using the ModernGraham method one can review a company’s historical accomplishments and determine an intrinsic value that can be compared across industries.  What follows is a stock analysis showing a specific look at how Endo International PLC (ENDP) fares in the ModernGraham valuation model.

ENDP Chart

ENDP data by YCharts

To read the details of this valuation, you must be logged in as a premium member. If you are not a premium member, please consider becoming one.

Premium members can view a full ModernGraham valuation of the company and have access to download a PDF version of the valuation for easy reference. Recent valuations of the components of the Dow Jones Industrial Average are available for free members, including this one of Microsoft Corporation.  In addition, here is a post detailing what can be found within each individual company’s valuation.

Learn More About Premium Membership

Useful Links:

ModernGraham tagged articles Morningstar
Google Finance MSN Money
Yahoo Finance Seeking Alpha
GuruFocus SEC Filings

Most Recent Balance Sheet Figures

Balance Sheet Information 3/1/2017
Total Current Assets $2,332,721,000
Total Current Liabilities $2,059,164,000
Long-Term Debt $8,224,559,000
Total Assets $13,218,650,000
Intangible Assets $10,138,192,000
Total Liabilities $11,030,597,000
Shares Outstanding (Diluted Average) 223,014,000

Earnings Per Share History

EPS History
Next Fiscal Year Estimate $3.73
Dec2016 -$15.03
Dec2015 -$7.59
Dec2014 -$4.60
Dec2013 -$5.72
Dec2012 -$6.40
Dec2011 $1.55
Dec2010 $2.20
Dec2009 $2.27
Dec2008 $2.06
Dec2007 $1.69
Dec2006 $1.03
Dec2005 $1.52
Dec2004 $1.08
Dec2003 $0.53
Dec2002 $0.30
Dec2001 -$0.40
Dec2000 -$1.97
Dec1999 $0.05

Earnings Per Share – ModernGraham History

EPSmg History
Next Fiscal Year Estimate -$5.28
Dec2016 -$9.14
Dec2015 -$5.65
Dec2014 -$3.99
Dec2013 -$2.86
Dec2012 -$0.84
Dec2011 $1.94
Dec2010 $2.04
Dec2009 $1.88
Dec2008 $1.62
Dec2007 $1.32
Dec2006 $1.06
Dec2005 $0.91
Dec2004 $0.38
Dec2003 -$0.08
Dec2002 -$0.39
Dec2001 -$0.65

Recommended Reading:

Other ModernGraham posts about the company

Endo International plc Analysis – Initial Coverage $ENDP

Other ModernGraham posts about related companies

Mylan NV Valuation – March 2017 $MYL
Amgen Inc Valuation – March 2017 $AMGN
Celgene Corporation Valuation – March 2017 $CELG
Ligand Pharmaceuticals Inc Valuation – Initial Coverage $LGND
Pfizer Inc Valuation – March 2017 $PFE
Supernus Pharmaceuticals Inc Valuation – Initial Coverage $SUPN
Lannett Company Inc Valuation – Initial Coverage $LCI
Spectrum Pharmaceuticals Inc Valuation – Initial Coverage $SPPI
Abbott Laboratories Valuation – January 2017 $ABT
Johnson & Johnson Valuation – January 2017 $JNJ


The author did not hold a position in any company mentioned in this article at the time of publication and had no intention of changing that position within the next 72 hours.  See my current holdings here.  This article is not investment advice; any reader should speak to a registered investment adviser prior to making any investment decisions.  ModernGraham is not affiliated with the company in any manner.  Please be sure to review our detailed disclaimer.

Tags: , , , , ,

Leave a Reply

Your email address will not be published. Required fields are marked *

More Stories From Pharmaceuticals

About Benjamin Clark